儿童心室辅助装置作为心脏移植桥接的国际多中心队列演变
该研究基于儿科心脏移植研究数据库,分析了1993年至2015年间<18岁儿童使用心室辅助装置(VAD)或体外膜肺氧合(ECMO)后转VAD桥接至心脏移植的演变。结果显示,VAD作为首选装置的患者移植率79%、死亡率14%,优于ECMO转VAD者的69%和24%;心肌病患者的移植率84%、等待期死亡率9%,均优于先天性心脏病患者的55%和36%。总体生存率在VAD支持与无支持者间无差异。
要点
- VAD作为首选装置桥接移植的预后优于ECMO后转VAD。
- 心肌病患者VAD桥接移植的等待期死亡率低于先天性心脏病患者。
- VAD支持与无支持患者的2年及20年生存率无显著差异。
核心结论
- 过去二十余年儿童机械循环支持技术显著进步,扩大了桥接至心脏移植的能力且未损害移植后结局。
- 新生儿和先天性心脏病患者仍是重大挑战。
研究设计与样本
- 基于儿科心脏移植研究数据库的国际多中心队列研究。
主要发现
- 7135例等待名单患者中5145例接受心脏移植,995例(19.3%)接受VAD支持,其中113例为先天性心脏病。
- VAD首选组(n=821)较ECMO转VAD组(n=164)年龄更大、体型更大,且心肌病比例更高(80%)。
- VAD首选组移植率79%、死亡率14%;ECMO转VAD组分别为69%和24%。
- 心肌病患者移植率84%、等待期死亡率9%;先天性心脏病患者分别为55%和36%。
- VAD患者中2年生存率75% vs 无支持80%,20年生存率55% vs 54%,无差异。
关键数值与推荐
- 2005年后,耐久性VAD较临时性VAD移植后结局更优(p < 0.01)。
- 2005年后,连续流VAD较搏动流VAD移植后结局更优(p < 0.01)。
- VAD植入时机对移植后生存无影响(p = 0.65)。
- VAD患者中年龄>10岁比例从最早期的79%降至近期的34%,新生儿仍<1%。
临床怎么用
- 儿童桥接至心脏移植可优先考虑VAD作为初始机械支持。
- 心肌病患儿VAD桥接移植的等待期死亡率较低,先天性心脏病患儿需更谨慎评估。
- 2005年后优先选择耐久性和连续流VAD以改善移植后结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pediatric ventricular assist device (VAD) use has evolved dramatically over the last 2 decades. OBJECTIVES: This study sought to describe the evolution of VAD support to heart transplantation (HTx) in children in a large international multicenter cohort. METHODS: Using data from the Pediatric Heart Transplant Study, comparisons were made between children (<18 years) supported to HTx (January 1, 1993 to December 31, 2015) with VAD or extracorporeal membrane oxygenation (ECMO) to VAD support. RESULTS: Of 7,135 listed patients, 5,145 underwent HTx; 995 (19.3%) were supported by a VAD (113 with congenital heart disease [CHD]). Patients with a VAD as their first device (n = 821) were older, larger, and more likely to have cardiomyopathy (80%) than patients transitioned from ECMO to VAD (n = 164). In the VAD-only cohort, 79% underwent HTx and 14% died, compared with 69% and 24% in the ECMO-to-VAD cohort, respectively. Patients with cardiomyopathy achieved HTx 84% of the time, with a 9% waitlist mortality rate compared with 55% and 36%, respectively, for CHD. Among VAD-treated patients, 79% were age >10 years in the earliest era, a percentage decreasing to 34% more recently, though neonates still represent <1%. Overall, survival at 2 and 20 years showed no difference between VAD and no support (2 years: 75% vs. 80%; 20 years: 55% vs. 54%). Post-HTx outcomes were better for durable versus temporary VADs (p < 0.01) and for continuous versus pulsatile VADs (p < 0.01) from 2005 onward; timing of VAD had no impact on post-HTx survival (p = 0.65). CONCLUSIONS: For one-quarter of a century, major advances have occurred in mechanical support technology for children, thereby expanding the capability to bridge to HTx without compromising post-HTx outcomes. Significant challenges remain, especially for neonates and patients with CHD, but ongoing innovation portends improved methods of support during the next decade.
引用
- Dipchand AI, Kirk R, Naftel DC, et al. Ventricular Assist Device Support as a Bridge to Transplantation in Pediatric Patients. J Am Coll Cardiol. 2018. PMID: 30025576. doi:10.1016/j.jacc.2018.04.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。